fasedienol
fasedienol: developed by 1 company · 2 clinical trials tracked.
fasedienol evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could fasedienol → VTGN affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Vistagen Therapeutics, Inc. (VTGN) Social Anxiety Disorder; Social Anxiety Disorder (SAD) | Phase 3 |
Clinical Trials (2)
US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Fasedienol Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder, With an Open-Label Extension (PALISADE-4)
Primary endpoint: Subjective Units of Distress Scale (SUDS)
US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Fasedienol Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder, With an Open-Label Extension (PALISADE-3)
Primary endpoint: Subjective Units of Distress Scale (SUDS)
Frequently asked questions
Who is developing fasedienol?
fasedienol is being developed by Vistagen Therapeutics, Inc..
How many clinical trials involve fasedienol?
BioSniper tracks 2 clinical trials involving fasedienol.